We demonstrated that in about 60% of AITL/PTLC-NOS patients identical pathogenic TET2 and/or DNMT3A mutations were shared between AITL/PTCL-NOS and CH found in the BM or PB. This evidence concerns the gene TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma.